1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
SCWorx received a Nasdaq Hearings Panel decision to delist its common stock, which has been suspended from Nasdaq since April 14, 2026, and now trades on the OTCQB. The company says a September 16, 2026 private placement cured its publicly held shares deficiency and has asked the Panel to reconsider, but the Panel has not yet acted, and the outcome is uncertain for shareholders.
Nasdaq Hearings Panel decided on September 17, 2026 to delist the common stock; the company requested reconsideration on September 18, 2026.
The company says the private placement and related share issuances give it more than 500,000 publicly held shares, meeting the Publicly Held Shares Rule.
To regain Bid Price Rule compliance, the stock must close at or above $1.00 for 10 consecutive trading days on or before October 5, 2026.
If all purchasers terminate, the company would return an aggregate of $938,000 and cancel 350,000 shares and warrants; the deadline for termination notices is October 15, 2026.
Sarepta Therapeutics entered a settlement agreement with REGENXBIO, the Trustees of the University of Pennsylvania and Catalent to resolve pending patent infringement litigation and an related appeal over several patents. Sarepta will pay REGENXBIO a lump sum of $39.0 million, an amount it had already recorded as a litigation contingency charge in the second quarter of 2026. The settlement releases Sarepta from past infringement claims and includes covenants not to sue for ELEVIDYS and other AAVrh74-based products, which removes a source of legal uncertainty for shareholders.
Sarepta will pay REGENXBIO a $39.0 million lump sum within ten days of the September 23, 2026 Effective Date.
The $39.0 million matches a litigation contingency charge recorded in the three and six months ended June 30, 2026.
REGENXBIO and UPenn released claims up to the Effective Date and agreed not to sue over ELEVIDYS and other AAVrh74-based products under the UPenn Patents.
The Litigations will be dismissed with prejudice, and the settlement includes no admission of liability.
Gossamer Bio said it submitted a New Drug Application to the FDA in September 2026 for seralutinib to treat pulmonary arterial hypertension, its first NDA. The application relies on the Phase 3 PROSERA study as one adequate and well-controlled investigation, supported by the Phase 2 TORREY study. The FDA has not yet decided whether to accept the application for filing, which the company expects could happen later this year.
NDA for seralutinib in PAH submitted to the FDA in September 2026, the company's first NDA
Submission follows a Pre-NDA Type B meeting with the FDA in June 2026 and the FDA's written meeting minutes
FDA will decide whether to accept the NDA for filing after its initial review, which the company anticipates could occur later this year
REGENXBIO and the University of Pennsylvania agreed to settle patent infringement litigation with Sarepta Therapeutics and Catalent over Sarepta's ELEVIDYS gene therapy. Sarepta will pay REGENXBIO $39.0 million within 10 days of the settlement's effective date, and the parties will end the ongoing patent litigation.
Sarepta will pay $39.0 million to REGENXBIO within 10 days of the settlement's effective date.
The settlement covers U.S. Patent No. 10,526,617 and U.S. Patent No. 11,680,274, related to SRP-9001 (ELEVIDYS).
REGENXBIO and UPenn release current infringement claims and agree to a covenant not to sue for future claims on AAVrh74-based Sarepta gene therapy products.
The full agreement is expected to be filed with the Form 10-Q for the quarter ending September 30, 2026.
Greenland Technologies Holding Corporation received a Nasdaq letter on September 22, 2026 confirming it has regained compliance with the $1.00 minimum bid price requirement. The company's Class A ordinary shares closed at $1.00 or above for 10 consecutive business days from September 8 through September 21, 2026, and Nasdaq has closed the matter. For shareholders, this removes the risk of delisting over the bid price issue.
Nasdaq notified the company on March 12, 2026 that its Class A ordinary shares had closed below $1.00 for 30 consecutive business days
On September 10, 2026, Nasdaq granted an additional 180-day period, to March 8, 2027, to regain compliance
On September 22, 2026, Nasdaq confirmed compliance after 10 consecutive business days at or above $1.00, from September 8 through September 21, 2026
Nasdaq approved Lakeshore Acquisition III Corp.'s application to move the listing of its units, ordinary shares and rights from the Nasdaq Global Market to the Nasdaq Capital Market. The company's securities will keep trading under the existing symbols, and Nasdaq says the Capital Market operates in substantially the same manner, though listed companies must still meet its financial and governance requirements.
Nasdaq approval received on September 22, 2026
Transfer to Nasdaq Capital Market takes effect at market open on September 24, 2026
CytoSorbents said it regained compliance with Nasdaq's $1.00 minimum bid price requirement after its closing bid price was at or above $1.00 for 10 consecutive trading sessions ending September 21, 2026, and Nasdaq closed that matter on September 22, 2026. The company still has not met Nasdaq's $35 million minimum market value of listed securities requirement, which it must meet by December 28, 2026, or it will receive a delisting notice, and the company states there is no assurance it will maintain its Nasdaq listing.
Nasdaq notified the company on September 22, 2026 that it regained compliance with the $1.00 minimum bid price requirement and closed the matter.
The company must have listed securities worth at least $35 million for 10 consecutive business days by December 28, 2026 to regain compliance with the market value requirement.
The company is evaluating actions and may consider increasing stockholders' equity to at least $2.5 million.
If the company does not regain compliance by December 28, 2026, it will receive a delisting notice and may appeal.
Astrana Health said social engineering attacks, in which threat actors impersonated company personnel and spoofed its main phone number, led to unauthorized activity in its environment. The company has determined the incident is material and believes certain private or confidential information was accessed or acquired, but the full scope remains under investigation. The company currently does not expect a material effect on its financial condition and results of operations, though it cannot yet estimate the full impact.
Company determined the incident is material as of September 22, 2026, citing the potential confidential and sensitive nature of the data involved.
Threat actors impersonated Company personnel and spoofed the main corporate telephone number to contact employees seeking unauthorized system access.
Company engaged a third-party forensics firm, notified law enforcement, and is notifying state and federal regulators and payer partners.
Company maintains cybersecurity insurance but says coverage may not be sufficient to cover all losses.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.